ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0884

Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus

Linda Hiraki1, Fangming Liao1, Dafna Gladman2, Ker-Ai Lee3, Zahi Touma4, Joan Wither5, Richard Cook3 and Murray Urowitz6, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, 4University of Toronto, Mississauga, ON, Canada, 5University Health Network, Toronto, ON, Canada, 6Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Disease Activity, genetics, outcomes, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Genetics and gene expression has been shown to correlate with systemic lupus erythematosus (SLE) disease severity. Our aim was to identify genetic risk loci for disease activity measures over time, representing disease activity burden.

Methods: The cohort study included participants from a tertiary care centre dedicated Lupus Clinic. Participants all met ≥4 of the ACR/SLICC classification criteria for SLE or 3 criteria and a positive biopsy. All participants had prospectively collected clinical data including repeated measures of disease activity evaluated with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). We restricted to participants with a first Lupus clinic visit within 3 years of SLE diagnosis and at least 2 clinic visits within 5 years. Participants were genotyped on the Illumina Multi-Ethnic Global Array, Global Screening Array or Omni 1-Quad array. Ungenotyped SNPs were imputed and ancestry was inferred using principal components (PCs) (1000 Genomes Project reference). The outcome was adjusted mean SLEDAI-2K and corticosteroids (AMSG), the calculated area under the curve of SLEDAI-2K over time, accounting for corticosteroid dose. Continuous square-root of AMS-G was the outcome of interest, transformed to improved normality. We included variants with minor allele frequency (MAF) of ≥0.01 and imputation quality r2 >0.3. Genome-wide additive allelic linear regression models were adjusted for sex and 5 PCs, stratified by array (MEGA+GSA and OMNI) and results were meta-analyzed using inverse variance weighting. A genome-wide significance threshold (p< 5x10-8) was used to indicate statistical significance.

Results: The cohort included 538 individuals with SLE. The majority (75%) had a first clinic visit within 1 year of SLE diagnosis. The majority were of European ancestry (54%) with 16% of East Asian ancestry and 12% African ancestry. The median ASMG was 5.5 (IQR 3.2, 8.8). Meta-GWAS identified a genome-wide significant SNP for ASMG (rs4561613) on chromosome 2 intronic to AGAP1 (Beta 0.34, SE 0.06, P=4.2×10-9) (Figure). The overall MAF is 0.43, with a higher risk allele frequency for increased ASMG in non-European ancestral groups (0.67 in African ancestry; 0.41 East Asian ancestry) compared to those of European ancestry (0.36).

Conclusion: We identified a genome-wide significant locus for SLE disease activity burden as measured by AMSG. Variants in AGAP1 has been linked with body mass index and red blood cell indices. The mechanism by which AGAP1 variants impact disease activity and severity in SLE is unclear. Future studies are required to replicate these findings in independent cohorts.

Figure. Manhattan plot for meta-genome-wide association of adjusted mean SLEDAI and corticosteroid exposure over time (AMSG).


Disclosures: L. Hiraki, Novartis, 6; F. Liao, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Celgene, 2, 5, Bristol Myers Squibb, 2, 5; K. Lee, None; Z. Touma, AbbVie Inc, 2, UCB Biopharma SRL, 2, Sarkana Pharma Inc., 1, 4, Janssen Inc., 2, GlaxoSmithKline Inc., 6; J. Wither, None; R. Cook, None; M. Urowitz, GlaxoSmithKline, 2, 5, 6, UCB, 2, Lilly, 6, AstraZeneca, 2.

To cite this abstract in AMA style:

Hiraki L, Liao F, Gladman D, Lee K, Touma Z, Wither J, Cook R, Urowitz M. Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/genetics-of-longitudinal-disease-activity-in-adults-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetics-of-longitudinal-disease-activity-in-adults-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology